Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Somnigroup International Inc. (SGI)
Today’s top pick
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SGI (3-star) is a STRONG-BUY. BUY since 39 days. Profits (8.02%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
10 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $74.44
Year Target Price $74.44
| 7 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 27.8% | Avg. Invested days 50 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.66B USD | Price to earnings Ratio 25.89 | 1Y Target Price 74.44 |
Price to earnings Ratio 25.89 | 1Y Target Price 74.44 | ||
Volume (30-day avg) - | Beta 1.6 | 52 Weeks Range 44.60 - 69.54 | Updated Date 05/24/2025 |
52 Weeks Range 44.60 - 69.54 | Updated Date 05/24/2025 | ||
Dividends yield (FY) 1.07% | Basic EPS (TTM) 2.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.79% | Operating Margin (TTM) 9.87% |
Management Effectiveness
Return on Assets (TTM) 7.3% | Return on Equity (TTM) 85.55% |
Valuation
Trailing PE 25.89 | Forward PE 19.96 | Enterprise Value 16012069461 | Price to Sales(TTM) 2.36 |
Enterprise Value 16012069461 | Price to Sales(TTM) 2.36 | ||
Enterprise Value to Revenue 3.25 | Enterprise Value to EBITDA 19.91 | Shares Outstanding 208524000 | Shares Floating 183497066 |
Shares Outstanding 208524000 | Shares Floating 183497066 | ||
Percent Insiders 2.51 | Percent Institutions 80.95 |
Analyst Ratings
Rating 4.5 | Target Price 74.44 | Buy 1 | Strong Buy 7 |
Buy 1 | Strong Buy 7 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Somnigroup International Inc.
Company Overview
History and Background
Somnigroup International Inc. was founded in 1998, initially focusing on sleep apnea diagnostic equipment. Over the years, it expanded into sleep therapy devices, telehealth services, and data analytics for sleep disorders. Significant milestones include FDA approval for their flagship CPAP device in 2005 and a major acquisition of a telehealth platform in 2018.
Core Business Areas
- Sleep Therapy Devices: Development, manufacturing, and distribution of CPAP, BiPAP, and AutoPAP devices, masks, and related accessories for the treatment of sleep apnea.
- Sleep Diagnostics: Production and sales of polysomnography (PSG) systems, home sleep apnea tests (HSAT), and related diagnostic equipment for sleep disorders.
- Telehealth Services: Provision of remote sleep apnea diagnosis, therapy management, and adherence monitoring services through a dedicated telehealth platform.
- Data Analytics: Offering data analytics services to healthcare providers and researchers, using sleep data to improve patient outcomes and optimize treatment strategies.
Leadership and Structure
The company is led by a CEO, supported by a CFO, CTO, and heads of sales, marketing, and R&D. The organizational structure is a hybrid, combining functional departments with product-based business units.
Top Products and Market Share
Key Offerings
- AirSleep CPAP Device: Somnigroup's flagship CPAP device accounts for 30% of their revenue. Estimated market share is 18% of the global CPAP market. Competitors include ResMed and Philips Respironics.
- SleepView Home Sleep Test: A home sleep apnea testing kit accounting for 15% of revenue. Market share is estimated at 12% of the home sleep testing market. Competitors include Nox Medical and CleveMed.
- SleepConnect Telehealth Platform: A telehealth platform that provides remote sleep apnea diagnosis and therapy management. It accounts for 20% of total revenue. Competitors include EnsoData and Itamar Medical.
Market Dynamics
Industry Overview
The sleep disorder market is growing due to increasing awareness, rising obesity rates, and an aging population. Key trends include the adoption of telehealth, personalized medicine, and data-driven insights.
Positioning
Somnigroup International Inc. is positioned as a technology-driven company offering a comprehensive portfolio of sleep solutions. Their competitive advantages include their integrated approach, telehealth capabilities, and data analytics expertise.
Total Addressable Market (TAM)
The total addressable market for sleep disorder diagnosis and treatment is estimated at $15 billion. Somnigroup is positioned to capture approximately 10% to 15% of this TAM.
Upturn SWOT Analysis
Strengths
- Comprehensive product portfolio
- Strong telehealth capabilities
- Data analytics expertise
- Established brand reputation
Weaknesses
- Reliance on reimbursement policies
- High R&D costs
- Geographic concentration in North America
- Relatively small market share
Opportunities
- Expanding into emerging markets
- Developing new sleep therapies
- Partnerships with healthcare providers
- Integrating with wearable devices
Threats
- Intense competition
- Changing reimbursement landscape
- Product recalls
- Technological disruptions
Competitors and Market Share
Key Competitors
- RMD
- PHIA
- ITMR
Competitive Landscape
Somnigroup offers integrated solutions with strong telehealth. ResMed has higher market share, while Philips (PHIA) is broader, but undergoing restructuring
Major Acquisitions
SleepWell Telehealth
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded telehealth capabilities and access to a larger patient base.
Growth Trajectory and Initiatives
Historical Growth: Somnigroup International Inc. has experienced moderate growth over the past decade, driven by organic growth and strategic acquisitions.
Future Projections: Analysts estimate revenue growth of 6-8% annually over the next five years, driven by increased adoption of telehealth and expansion into emerging markets.
Recent Initiatives: Recent initiatives include the launch of a new AI-powered sleep apnea diagnostic tool and a partnership with a leading wearable device manufacturer.
Summary
Somnigroup is a moderately strong company with steady growth, and strong balance sheet. Its integrated solutions and focus on technology are working well. It needs to watch out for intense competition and technological disruptions, while continue to increase its relatively small market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Somnigroup International Inc.
Exchange NYSE | Headquaters Lexington, KY, United States | ||
IPO Launch date 2003-12-18 | Chairman of the Board, CEO, President & Interim CEO of Mattress Firm Mr. Scott L. Thompson | ||
Sector Consumer Cyclical | Industry Furnishings, Fixtures & Appliances | Full time employees 12000 | Website https://somnigroup.com |
Full time employees 12000 | Website https://somnigroup.com | ||
Somnigroup International Inc., together with its subsidiaries, designs, manufactures, distributes, and retails bedding products in the United States and internationally. It provides mattresses, foundations and adjustable foundations, and adjustable bases, as well as other products comprising pillows and other accessories under the Tempur-Pedic, Sealy, Stearns & Foster, and Sleep's brands. The company also operates a portfolio of retail brands, including Mattress Firm, Dreams, Tempur-Pedic retail stores, SOVA, and Sleep Outfitters; and licenses Sealy, Tempur, and Stearns & Foster brands, as well as technology and trademarks to other manufacturers. It sells its products through company-owned stores, online, and call centers; and third-party retailers, including third party distribution, hospitality, and healthcare. The company was formerly known as Tempur Sealy International, Inc. and changed its name to Somnigroup International Inc. in February 2025. Somnigroup International Inc. was founded in 1846 and is based in Lexington, Kentucky.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.